Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Summary
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.
Official title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2025-02-25
Completion Date
2025-08
Last Updated
2025-03-05
Healthy Volunteers
No
Interventions
HRS-1893
HRS-1893 tablet.
HRS-1893 placebo
HRS-1893 tablet placebo.
Locations (1)
Fuwai Hospital
Beijing, Beijing Municipality, China